Abbott Laboratories Corporation

Abbott Point of Care Inc.

Sergey Y Tetin

Qiaoqiao Ruan

Joseph P Skinner

Gordon Bruce Collier

Dan Wang

Susan Gayda

Barry Lee Dowell

Sylvia C Saldana

Mark R Pope

M Felicia Bogdan

Kerry M Swift

Richard Haack

Brenda Calfin

Patrick J Macdonald

Suresh M Desai

Joan D Tyner

Mark A Hayden

Andrew G Fischer

David J Hawksworth

Anthony Scott Muerhoff

Robert N Ziemann

Jeffrey B Huff

Larry G Birkenmeyer

Thomas P Leary

Bryan C Tieman

Bailin Tu

Frank C Grenier

Xiaoxing Qiu

Robert William Siegel

John C Prostko

Ryan F Workman

Sophie Laurenson

Shelley R Holets-McCormack

Pathik H Soni

Zhen Lin

Lyle Yarnell

Edward T Olejniczak

Dustin House

Lei Qiao

Edna Prieto-Ballengee

Peter J Karabatsos

Andrew S Schapals

Stefan Hershberger

M Shawn Murphy

Andrew T Fischer

Edna M Prieto-Ballengee

Felicia Bogdan

Barry L Dowell

Silvia C Saldana

Ruan Qiaoqiao

Thomas Leary

The disclosure provides methods of analyzing an analyte of interest in a biological sample using fluorescent agents and macroconjugates which comprise a core containing a cross-linked polymer or protein, tags, specific binding members or fragments thereof, and optionally carrier proteins. Also provided are methods of analyzing two or more analytes of interest in a biological sample in a single assay using microparticles and detection conjugates comprising different fluorophore labels, acquiring transmitted light and fluorescent images of the microparticles, and using a customized image analysis process to analyze the acquired images.

Direct detection of single molecules on microparticles

A method for analyzing the results of a ligand-receptor binding assay comprising the steps of: More particularly, the ligand-receptor binding assay involves the steps of combining appropriate reagents in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is directly proportional to the amount of ligand present in the sample. Alternatively, the ligand-receptor binding assay involves the steps of combining appropriate reagents to perform a ligand-receptor binding assay in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is inversely proportional to the amount of analyte present in the sample.

Spatially resolved ligand-receptor binding assays

Methods, devices, and systems for analyte analysis using a nanopore are disclosed. The methods, devices, and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second binding member and correlating the presence and/or the number of tags to presence and/or concentration of the analyte. Certain aspects of the methods do not involve a tag, rather the second binding member may be directly detected/quantitated. The detecting and/or counting may be performed by translocating the tag/second binding member through a nanopore. Devices and systems that are programmed to carry out the disclosed methods are also provided.

Devices and methods for sample analysis

Provided herein are assays and kits useful for avoiding 'prozone phenomenon' or 'hook effect' and which expand the range of accurately measurable analyte concentrations.

Assay with increased dynamic range

A method for analyzing the results of a ligand-receptor binding assay comprising the steps of:

The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).

TSH antibodies for point-of-care immunoassay formats

The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).

TSH immunoassays and processes for performing TSH immunoassays in the presence of endogenous contaminants in restricted wash formats

Provided herein are kits and methods for assays with internal calibration.

Assay with internal calibration

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

Growing community of inventors

Lindenhurst, IL, United States of America

Sergey Y Tetin